Synonyms: ATA-101 | ATA101 | compound 7a [PMID 23126648] [4] | TC-5619 | TC5619
Compound class:
Synthetic organic
Comment: Bradanicline is an investigational agonist of neuronal α7 subunit-containing nicotinic acetylcholine receptors [4].
|
|
No information available. |
Summary of Clinical Use ![]() |
Bradanicline has completed Phase 2 clinical trials as a potential treatment for the cognitive impairment associated with schizophrenia [3] and attention deficit/hyperactivity disorder (ADHD). Attenua are repurposing bradanicline as a novel intervention for refractory chronic cough [1]. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT03622216 | A Dose Escalation Study of Bradanicline in Refractory Chronic Cough | Phase 2 Interventional | Attenua, Inc. |